Same Drug Class

Ipilimumab vs Osimertinib

Ipilimumab vs Osimertinib: Overview

This comparison examines the pharmacological differences between Ipilimumab and Osimertinib.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days; Osimertinib β€” 48 hours.

Chemical Properties

Molecular Formula: Osimertinib β€” C28H33N7O2.

Molecular Weight: Osimertinib β€” 499.6050 g/mol.

Type: Ipilimumab β€” Antibody; Osimertinib β€” Small molecule.